Yoshitaka Sekido

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Epithelial Mesenchymal Transition

Genome Wide Identification

Top Venues

Molecular cancer research : MCR

Cell death discovery

Pathology international

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Takayama Koichi
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics (2023)
Koya Suzuki, Masaki Tange, Ryota Yamagishi, Hiroyuki Hanada, Satomi Mukai, Tatsuhiro Sato, Takeshi Tanaka, Tomohiro Akashi, Kenji Kadomatsu, Tohru Maeda, Takashi Miida, Ichiro Takeuchi, Hiroshi Murakami, Yoshitaka Sekido, Yuko Murakami-Tonami
SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma. Cell death discovery 8 (1) (2022)
Lin Yue, Yaguang Luo, Li Jiang, Yoshitaka Sekido, Shinya Toyokuni
PCBP2 knockdown promotes ferroptosis in malignant mesothelioma. Pathology international 72 (4) (2022)
Aditya Wirawan, Ken Tajima, Fumiyuki Takahashi, Yoichiro Mitsuishi, Wira Winardi, Moulid Hidayat, Daisuke Hayakawa, Naohisa Matsumoto, Kenta Izumi, Tetsuhiko Asao, Ryo Ko, Naoko Shimada, Kazuya Takamochi, Kenji Suzuki, Masaaki Abe, Okio Hino, Yoshitaka Sekido, Kazuhisa Takahashi
A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma By Suppressing LSD1. Molecular cancer research : MCR (2021)
Tatsuhiro Sato, Hayao Nakanishi, Ken Akao, Maho Okuda, Satomi Mukai, Tohru Kiyono, Yoshitaka Sekido
Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively. Cancer cell international 21 (1) (2021)